Register for our free email digests:
Latest From Genset SA
The eagle has landed for Australian drug discoverer Pharmaxis in the form of a major deal with Boehringer Ingelheim for a non-alcoholic steatohepatitis (NASH) treatment, and the Sydney-based firm says it is ready to soar again following the transaction.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Cytokinetics Inc.
- Senior Management
Robert I Blum, Pres. & CEO
Sharon Barbari, EVP, Fin. & CFO
Andrew A Wolff, MD, SVP, CMO
Elisabeth A Schnieders, PhD, SVP, Bus. Dev.
Scott R Jordan, VP, Commercial Dev.
- Contact Info
Phone: (650) 624-3000
280 East Grand Ave.
S. San Francisco, CA 94080
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.